This composite educational graphic illustrates the complexity of Minimal Residual Disease (MRD) assessment in Multiple Myeloma (MM). The left panel features a full-body PET-CT maximum intensity projection (MIP) showing multifocal, hypermetabolic skeletal and extramedullary lesions (patchy involvement), emphasizing the utility of imaging for detecting non-uniform disease distribution. The right panel displays a pathophysiology diagram of clonal and cellular heterogeneity. It depicts a 'Tumor Ancestor' cell diverging into four distinct subclones. Each subclone undergoes a horizontal maturation process: subclone propagating cell, B-cell, activated B-cell, preplasmablast, plasmablast, and mature plasma cell. The diagram overlays three diagnostic detection windows: flow cytometry (FCM), which specifically targets the mature plasma cell stage; ASO-PCR, which captures the entire clonal lineage from progenitor to mature cell; and Next-Generation Sequencing (NGS), represented by a barcode, which covers the global tumor population. The figure highlights how cellular maturation and genetic subclonal variation impact the sensitivity and reach of different MRD monitoring techniques.

Multiparameter flow cytometry immunophenotyping of bone marrow plasma cells demonstrates clonal kappa-restricted population consistent with plasma cell myeloma. Gating on CD45, CD38, and CD138 identifies plasma cells, which reveal dim surface kappa light chain expression while cytoplasm shows bright kappa positivity; normal/reactive plasma cells display polyclonal cytoplasmic immunoglobulins and lack overt surface light chain restriction. The left panel illustrates plasma cells with a typical myeloma phenotype (CD45 dim, CD38 high, CD138 positive) against a background of polyclonal B cells and blasts; the right panel highlights the clonal kappa-restricted cluster, with dim surface κ but strong cytoplasmic κ staining, contrasting with lambda-restricted or kappa-negative populations. These features support clonality and enable minimal residual disease assessment after therapy. The assay complements morphology and serum paraprotein studies by providing quantitative, single‑cell sensitivity to detect residual malignant plasma cells below conventional thresholds. Diagnostic significance lies in confirming clonal plasma cell dyscrasia and guiding therapeutic decisions, prognosis, and MRD-directed treatment intensity. Normal variants include polyclonal plasma cells and non-neoplastic B cells, which serve as internal controls. Differential considerations include reactive plasmacytosis with polyclonal light chains and small clonal expansions. Clinically, flow cytometry MRD monitoring informs response assessment, risk stratification, and potential relapse prediction in multiple myeloma.

Flow cytometry immunophenotyping of a hematologic specimen reveals clonal plasma cell proliferation consistent with a plasma cell neoplasm. In the left panel, CD38 APC:Red-A log versus SSC-A linear delineates a large, bright CD38-positive plasma cell gate, marked by a dense cluster at higher CD38 intensity and substantial forward and side scatter typical of plasma cells. The right panel demonstrates intracellular light-chain analysis with CytoKappa FITC:Blue D versus Ig light chain axis, showing a dominant κ-restricted subset comprising the vast majority of κ-positive events (approximately 98%), with minimal λ-expressing cells. The data indicate strong cytoplasmic κ light-chain expression while surface immunoglobulin is absent or markedly reduced on these neoplastic cells, supporting clonality. CD138 is strongly expressed, consistent with plasmacytic differentiation. The observed immunophenotype, including CD38 bright and CD138 positivity with κ light-chain restriction, favors a malignant plasma cell process over reactive plasmacytosis. Additional markers commonly described in myeloma panels (e.g., CD19 negative/dim, CD56 variable) may be inferred but are not shown. Clinically, this pattern is critical for classification, diagnostic confirmation of plasma cell dyscrasia, and monitoring via minimal residual disease assessment, guiding staging and therapeutic decisions. This annotation is suitable for educational databases and clinical decision-support tools in hematology and research.

Imaging modality and technique: light microscopy of an H&E stained bone marrow trephine biopsy, demonstrating focal clusters of immature plasma cells within otherwise normal hematopoietic marrow. Primary subject: multiple myeloma plasma cell neoplasm with focal involvement in the marrow rather than uniform infiltration. Specimen: bone marrow biopsy core from iliac crest; perspective: microscopic cellular detail. Visual features: islands of small, tightly packed cells with oval to irregular nuclei, scant cytoplasm, condensed chromatin, and occasional prominent nucleoli; cytoplasm scant but adequate for recognition of plasma cell lineage. Surrounding marrow shows preserved hematopoiesis with trilineage elements; no overt osteoid or fibrotic bands described. Pathology: tumor cells exhibit high nuclear-to-cytoplasmic ratio and dysplastic, immature morphology; dispersed chromatin; some cells with conspicuous nucleoli; distribution irregular, with patches of tumor cells separated by intervening normal marrow. Diagnostic significance: histologic pattern supports early/patchy marrow involvement by plasma cell neoplasm, consistent with multiple myeloma; sampling error is possible in focal disease, emphasizing the need for regional marrow sampling and integration with ancillary studies (flow cytometry, immunoglobulin studies, cytogenetics). Clinical relevance: correlates with systemic disease burden, guides staging, prognosis, and treatment planning; spatial heterogeneity underscores importance of comprehensive marrow evaluation for monitoring response and minimal residual disease assessment.